NuVasive, Inc., a medical device company, develops and markets minimally disruptive surgical products and procedurally integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal products include Maximum Access Surgery, a minimally disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics. Its spine surgery product line offerings comprise products for the thoracolumbar and the cervical spine, which are primarily used to enable surgeons to access the spine to perform restorative and fusion procedures in a minimally-disruptive fashion. The company's biologics products include Osteocel Plus and Pro, a cellular bone matrix; Formagraft, a collagen-based synthetic bone substitute; AttraX, a synthetic bone graft material; and Propel DBM, a moldable demineralized bone matrix putty and gel. Its IOM services are used for onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company also provides implants used for interbody disc height restoration; and fixation products, including pedicle screws, rods, and plates. In addition, it offers Integrated Global Alignment platform for assessing, preserving, and restoring spinal alignment; MAGEC-early onset scoliosis, a spinal bracing and distraction system; and PRECICE, a limb lengthening system. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly-employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was founded in 1997 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Phone858-909-1800
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.10 billion
Profitability
Miscellaneous
Employees2,600
Next Earnings Date5/7/2019 (Estimated)
OptionableOptionable
NuVasive (NASDAQ:NUVA) Frequently Asked Questions
What is NuVasive's stock symbol?
NuVasive trades on the NASDAQ under the ticker symbol "NUVA."
How will NuVasive's stock buyback program work?
NuVasive declared that its Board of Directors has authorized a share repurchase program on Wednesday, October 25th 2017, which permits the company to repurchase $100,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to repurchase shares of its stock through open market purchases. Stock repurchase programs are often an indication that the company's leadership believes its shares are undervalued.
How were NuVasive's earnings last quarter?
NuVasive, Inc. (NASDAQ:NUVA) announced its quarterly earnings results on Wednesday, February, 20th. The medical device company reported $0.69 earnings per share for the quarter, topping analysts' consensus estimates of $0.63 by $0.06. The medical device company had revenue of $288.30 million for the quarter, compared to analysts' expectations of $290.85 million. NuVasive had a net margin of 1.13% and a return on equity of 14.60%. The business's revenue was up 6.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.56 EPS. View NuVasive's Earnings History.
When is NuVasive's next earnings date?
What guidance has NuVasive issued on next quarter's earnings?
NuVasive updated its FY19 earnings guidance on Wednesday, February, 20th. The company provided earnings per share (EPS) guidance of $2.20-2.30 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.47. The company issued revenue guidance of $1.14-1.16 billion, compared to the consensus revenue estimate of $1.17 billion.NuVasive also updated its FY 2019 guidance to $2.20-2.30 EPS.
What price target have analysts set for NUVA?
16 brokerages have issued twelve-month target prices for NuVasive's shares. Their predictions range from $42.00 to $82.00. On average, they expect NuVasive's share price to reach $65.3333 in the next year. This suggests a possible upside of 15.3% from the stock's current price. View Analyst Price Targets for NuVasive.
What is the consensus analysts' recommendation for NuVasive?
16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NuVasive in the last year. There are currently 2 sell ratings, 7 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for NuVasive.
What are Wall Street analysts saying about NuVasive stock?
Here are some recent quotes from research analysts about NuVasive stock:
- 1. According to Zacks Investment Research, "NuVasive exited 2018 on a promising note with better-than-expected results. However, the contraction in margins is disappointing. Headwinds like pricing pressure, reimbursement issues and a competitive landscape are major downsides. Overall, NuVasive has underperformed the S&P 500 over the past three months. Meanwhile, the company witnessed revenue growth across all key operating segments. Robust sales figures in international markets buoy optimism. We are upbeat about the strong demand for several of the company’s recently-launched products in the U.S. Spinal Hardware business. Furthermore, NuVasive's latest receipt of 510(k) clearance from the FDA along with the CE mark approval for its Precice Bone Transport System looks encouraging." (2/25/2019)
- 2. Cantor Fitzgerald analysts commented, "We maintain our Neutral rating and 12-month PT of $50 on shares of NUVA. NUVA has faced a growing number of challenges over the past 18 months, particularly in its US business, which has pressured the stock. We think it is appropriate to remain on the sidelines until we gain more confidence in the reacceleration of US growth and OM improvement. $50 price target is based on a 10x EV/EBITDA multiple on our 2020 EBITDA estimate." (2/11/2019)
- 3. Needham & Company LLC analysts commented, "NUVA’s 3Q18 revenue beat while its EPS missed. Management raised revenue guidance but lowered EPS guidance. Organic growth increased to 8% in 3Q18 from 5% in 2Q18 as improved domestic growth offset slower international growth. Operating margin was 220 bps below consensus as management decided to exploit an improving spine market by reinvesting in SG&A (up 70 bps Y/Y) and R&D (up 50 bps Y/Y). Gross margin met consensus and West Carrollton remains on track to deliver 130-150 bps of margin benefit in 2019. While the margin performance is frustrating, we expect the stronger growth combined with in-sourcing to drive better margin performance in 2019 and reiterate our Buy rating." (10/31/2018)
Has NuVasive been receiving favorable news coverage?
Media stories about NUVA stock have been trending neutral recently, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. NuVasive earned a media sentiment score of 0.2 on InfoTrie's scale. They also gave media coverage about the medical device company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future.
Who are some of NuVasive's key competitors?
Some companies that are related to NuVasive include Hill-Rom (HRC), Insulet (PODD), Penumbra (PEN), ICU Medical (ICUI), Novocure (NVCR), Integra Lifesciences (IART), Globus Medical (GMED), Haemonetics (HAE), Tandem Diabetes Care (TNDM), Merit Medical Systems (MMSI), Glaukos (GKOS), Cantel Medical (CMD), Irhythm Technologies (IRTC), Mazor Robotics (MZOR) and Atrion (ATRI).
What other stocks do shareholders of NuVasive own?
Who are NuVasive's key executives?
NuVasive's management team includes the folowing people:
- Mr. Matthew W. Link, Pres (Age 44)
- Mr. Rajesh J. Asarpota, Exec. VP & CFO (Age 52)
- Dr. Peter M. Leddy, Exec. VP of People & Culture (Age 56)
- Mr. J. Christopher Barry, CEO & Director
- Mr. Jereme Sylvain, Chief Accounting Officer (Age 39)
Who are NuVasive's major shareholders?
NuVasive's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Eagle Asset Management Inc. (2.57%), Fisher Asset Management LLC (2.47%), Dimensional Fund Advisors LP (2.42%), Norges Bank (1.99%), Anchor Capital Advisors LLC (1.79%) and Victory Capital Management Inc. (1.78%). Company insiders that own NuVasive stock include Gregory T Lucier, Lesley H Howe, Matthew Link and Peter Michael Leddy. View Institutional Ownership Trends for NuVasive.
Which institutional investors are selling NuVasive stock?
NUVA stock was sold by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Victory Capital Management Inc., Eagle Asset Management Inc., Anchor Capital Advisors LLC, American Capital Management Inc., Raymond James & Associates, Dimensional Fund Advisors LP and Tamarack Advisers LP. View Insider Buying and Selling for NuVasive.
Which institutional investors are buying NuVasive stock?
NUVA stock was acquired by a variety of institutional investors in the last quarter, including Norges Bank, SG Capital Management LLC, Mesirow Financial Investment Management Equity Management, DNB Asset Management AS, American Century Companies Inc., Macquarie Group Ltd., Segall Bryant & Hamill LLC and Hsbc Holdings PLC. Company insiders that have bought NuVasive stock in the last two years include Gregory T Lucier and Peter Michael Leddy. View Insider Buying and Selling for NuVasive.
How do I buy shares of NuVasive?
Shares of NUVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is NuVasive's stock price today?
One share of NUVA stock can currently be purchased for approximately $56.68.
How big of a company is NuVasive?
NuVasive has a market capitalization of $2.93 billion and generates $1.10 billion in revenue each year. The medical device company earns $12.47 million in net income (profit) each year or $2.23 on an earnings per share basis. NuVasive employs 2,600 workers across the globe.
What is NuVasive's official website?
How can I contact NuVasive?
NuVasive's mailing address is 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-909-1800 or via email at [email protected]
MarketBeat Community Rating for NuVasive (NASDAQ NUVA)
MarketBeat's community ratings are surveys of what our community members think about NuVasive and other stocks. Vote "Outperform" if you believe NUVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NUVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
